This discovery has clear clinical translational value, particularly in colorectal cancer patients with TSC1 pathway abnormalities, where combining mTOR inhibitors may enhance the sensitivity to immune checkpoint therapy and expand the applicability of precision immunotherapy. Here, TSC1 is linked to colorectal cancer.